Deferred stent implantation in patients with ST segment elevation myocardial infarction with high thrombus burden |
| Author : Mohamed Abdel-shafy Tabl*, Khaled Emad El-Rabbat, Eman Said El-keshk and Gamal Mohamed Gharib |
| Abstract | Full Text |
Abstract :Recent guidelines recommend against deferred stenting as a routine strategy in STEMI patients.
Objectives: current study aimed to assess whether deferred stenting strategy in primary PCI might reduce angiographic or in-hospital major adverse cardiac events in comparison to immediate stenting.
Methods: one hundred patients of STEMI with high thrombus burden divided equally into; 50 patients (group 1) treated with immediate stenting and 50 patients (group 2) treated with deferred stenting. Procedural angiographic events were the primary endpoints, while in hospital MACE were designed as secondary endpoints. |
|
Safety of Thrombolytic therapy at emergency department vs coronary care unit: A comparative study of 100 patients at tertiary Cardiac care centre |
| Author : Sadia Saif, Rehana Khadim*, Muhammad Asad, Mubarra Nasir, Mir Waqas Baloch, Urooj Alam, Farhan Tuyyab and Sumia Aslam |
| Abstract | Full Text |
Abstract :Objective: To determine the safety of thrombolysis (streptokinase administration) at Emergency department with comparison to coronary care unit of AFIC& NIHD, Pakistan.
Study Design: Comparative cross-sectional study.
Place and Duration of Study: Emergency department and coronary care unit of Armed Forces Institute of Cardiology & National Institute of Heart Diseases Rawalpindi, Pakistan from December 2016 till May 2017. |
|
ROTEM and vitro reversal of warfarin with APCC |
| Author : Kornhall L, Wikander D, Strandberg K, Berntorp E and Schött U* |
| Abstract | Full Text |
Abstract :Background: Warfarin-treated patients with a prolonged Prothrombin Time (PT) can have a normal rotational thromboelastometry (ROTEM) clotting time (CT). A previous in vitro study found that activated prothrombin complex concentrates (APCC) could reverse an albumin-induced coagulopathy monitored with ROTEM, but that prothrombin complex concentrates (PCC) could not. The aim of this study was to investigate the ability of ROTEM to monitor the in vitro reversal of warfarin-induced coagulopathy using APCC and to define an APCC dose response. |
|